Literature DB >> 24530132

ECCO position challenged by European drug regulators.

Pekka Kurki1, Marie-Christine Bielsky2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24530132     DOI： 10.1016/j.crohns.2014.01.022

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  23 in total

1.  Accurate and reliable quantification of 25-hydroxy-vitamin D species by liquid chromatography high-resolution tandem mass spectrometry.

Authors:  Gerhard Liebisch; Silke Matysik
Journal:  J Lipid Res       Date:  2015-04-01       Impact factor: 5.922

Review 2.  What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?

Authors:  Antonia Busse; Diana Lüftner
Journal:  Breast Care (Basel)       Date:  2019-02-13       Impact factor: 2.860

3.  Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Authors:  Lot A Devriese; Petronella Els O Witteveen; Jantien Wanders; Kenneth Law; Geoff Edwards; Larisa Reyderman; William Copalu; Fuping Peng; Serena Marchetti; Jos H Beijnen; Alwin D R Huitema; Emile E Voest; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

4.  Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.

Authors:  Ravi Thadhani; Ruffy Guilatco; Jeffrey Hymes; Franklin W Maddux; Ajay Ahuja
Journal:  Am J Nephrol       Date:  2018-09-07       Impact factor: 3.754

5.  Population pharmacokinetics of deferiprone in healthy subjects.

Authors:  Francesco Bellanti; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

6.  Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives.

Authors:  Miklos Sebeszta; Alex Kudrin
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09

Review 7.  Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases.

Authors:  Joanna Sieczkowska; Dorota Jarzębicka; Monika Meglicka; Grzegorz Oracz; Jaroslaw Kierkus
Journal:  Therap Adv Gastroenterol       Date:  2016-05-22       Impact factor: 4.409

8.  Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.

Authors:  Thor Ostenfeld; Claire Beaumont; Jonathan Bullman; Maria Beaumont; Phillip Jeffrey
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 9.  Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials.

Authors:  Pritesh N Bodalia; Anthony M Grosso; Reecha Sofat; Raymond J Macallister; Liam Smeeth; Soraya Dhillon; Juan-Pablo Casas; David Wonderling; Aroon D Hingorani
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 10.  Biosimilars in the United States: Considerations for Oncology Advanced Practitioners.

Authors:  Kelley D Mayden; Paul Larson; Danielle Geiger; Holly Watson
Journal:  J Adv Pract Oncol       Date:  2015-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.